Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1982 May 17;60(10):479-88.
doi: 10.1007/BF01756093.

Arachidonic acid metabolites, hypertension and arteriosclerosis

Arachidonic acid metabolites, hypertension and arteriosclerosis

P C Weber et al. Klin Wochenschr. .

Abstract

The level of arterial blood pressure is set by complete interactions of several mechanisms which influence both blood flow in and resistance of the vascular system. An imbalance favouring elevation of vascular resistance or extracellular volume will result in hypertension. Such alterations may include increased activity of the sympathetic nervous system, of the renin-angiotensin system, or excessive secretion of mineralocorticoids. Of equal importance may be a reduced activity of blood pressure-lowering factors such as prostaglandins and the kallikrein-kinin system. This paper describes the possible significance of prostaglandins in the pathophysiology of hypertension and in degenerative vascular disease, based on their involvement in the control of vascular resistance, renal regulation of extracellular volume and platelet-vessel wall interactions. An abnormality in the biosyn-thesis of certain prostaglandin endoperoxide metabolites may lead to hypertension even without an increase in the activity of the classic blood-pressure-elevating systems. The contribution of prostaglandins for the development of hypertension and degenerative vascular disease may be based on an inherent abnormality of the prostaglandin system, as well as on the effects of major risk factors such as dietary intake of sodium and fat on prostaglandin synthesis. Specific blockade or stimulation of distinct biosynthetic pathways leading to antagonistically acting prostaglandins and nutritional manipulation of precursor fatty acids should lead to a better understanding of the pathomechanisms involved and may offer new strategies for therapy or prevention of these cardiovascular disorders.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Br Med J. 1980 Sep 13;281(6242):702-5 - PubMed
    1. Clin Sci (Lond). 1980 Dec;59 Suppl 6:125s-128s - PubMed
    1. Adv Prostaglandin Thromboxane Res. 1980;7:1047-52 - PubMed
    1. Prostaglandins Med. 1981 Feb;6(2):135-45 - PubMed
    1. Br Med Bull. 1978 May;34(2):129-35 - PubMed

MeSH terms

LinkOut - more resources